中国临床药理学杂志2019，Vol.35Issue(7)：701-702,705,3.DOI:10.13699/j.cnki.1001-6821.2019.07.029
血管紧张素转换酶抑制药联合血管紧张素Ⅱ受体阻断药治疗继发性局灶节段性肾小球硬化症患者的用药分析
Angiotensin converting enzyme inhibitor combined with angiotensin Ⅱ receptor blockers in the treatment of secondary focal segmental glomerular sclerosis in patients with drug use analysis
张利利 1马凌云 2陈超阳 1梁雁 1袁海龙 1周颖 2崔一民1
作者信息
- 1. 北京大学 第一医院 药剂科,北京 100034
- 2. 空军特色医学中心 药学部,北京 100142
- 折叠
摘要
Abstract
Objective To explore the role of clinical pharmacists in the treatment of secondary focal segmental sclerosis with angiotensin converting enzyme inhibitors (ACEI) combined with angiotensin Ⅱ receptor blockers (ARB) . Methods The clinical pharmacist participated in the clinical treatment process of a patient with secondary focal segmental glomerulus sclerosis treated by ACEI combined with ARB, confirmed the rationality of the treatment program, and closely monitored the changes of various laboratory indicators and clinical symptoms during the treatment process, and assisted the physician in adjusting the drug treatment program. Results and conclusion The clinical pharmacist participated in the adjustment of individualized treatment program and the implementation of pharmaceutical care, which effectively reduced the damage caused by adverse drug reactions to patients, and fully played the role of clinical pharmacist in the clinical treatment process.关键词
血管紧张素转换酶抑制药/血管紧张素Ⅱ受体阻断药/保肝药/局灶节段硬化/药学监护Key words
angiotensin converting enzyme inhibitors/angiotensin Ⅱ receptor blocker/hepatic protector focal/segment hardening/pharmaceutical care分类
医药卫生引用本文复制引用
张利利,马凌云,陈超阳,梁雁,袁海龙,周颖,崔一民..血管紧张素转换酶抑制药联合血管紧张素Ⅱ受体阻断药治疗继发性局灶节段性肾小球硬化症患者的用药分析[J].中国临床药理学杂志,2019,35(7):701-702,705,3.
